Society of Nuclear Medicine and Molecular Imaging

08/20/2026

What’s missing from the nuclear medicine community? JNM EIC Ken Herrmann thinks one of those things is controversial discussion. Good thing this episode of the JNM Podcast has it! But what was the disagreement? Tune in to the latest episode: The Equivalents Are Coming! FDA Approval Pathways for Nuclear Medicine, now streaming on SNMMI’s YouTube channel or your favorite podcast platform.

Thanks to our guest stars Thomas Hope and Aman Chauhan for their expertise!

This episode of the JNM Podcast was sponsored by Curium Pharma.

08/17/2026

Big nuc med news: FDA approves new Alzheimer’s PET imaging agent from Lantheus

Read more:

Tauklarify, also known as MK-6240, is a radiodiagnostic agent indicated for positron emission tomography scans of adults suspected of having the degenerative brain disease.

08/13/2026

LAST CALL: Apply now for a $100,000 research grant opportunity!

This grant aims to fund a research project focused on advancing ILC imaging to improve patient outcomes. Elevate your research and apply today.

Learn More: https://ow.ly/peZ050ZnZhz

08/10/2026

Leadership creates opportunities, not just for yourself, but for an entire community. Our new monthly Member Monday Spotlight series celebrates the leaders, innovators, educators, and volunteers whose passion is driving our profession forward.

Charlie Flores is a dedicated leader in nuclear medicine with a passion for advancing the profession through collaboration, education, and advocacy.

One of his most significant contributions to SNMMI was spearheading the Society of Nuclear Medicine and Molecular Imaging of Puerto Rico, officially becoming SNMMI's first new chapter since 1986. Thanks to Charlie's leadership, nuclear medicine professionals across Puerto Rico now have greater opportunities to connect, learn, and grow within the SNMMI community. His story is a reminder that one member can make a lasting impact on the profession.

Inspired by leaders like Charlie? Join or renew your SNMMI membership and become part of a community that's shaping the future of nuclear medicine, one member at a time. https://snmmi.org/Shared_Content/COMMON/Sign_In.aspx

08/05/2026

As radiopharmaceutical development advances at an unprecedented pace and clinical trials expand globally, now is a critical time to strengthen U.S. pathways. SNMMI is bringing the radiopharmaceutical community together to discuss the challenges and opportunities shaping first-in-human research.

Join experts from academia, industry, and the regulatory community, including the FDA, on September 17, 2026, for a FREE one-day virtual workshop, First-in-Human Radiopharmaceutical Trial, exploring the scientific, clinical, and regulatory considerations influencing early-stage radiopharmaceutical development.

Learn More at https://snmmi.org/fih

08/04/2026

Register for our upcoming webinars. FREE for members!

August 11: Expanding Clinical Services with PET/CT

August 14: SNMMI Theranostics Tumor Board

Check out the upcoming webinars here: https://snmmi.org/Web/Education-and-Meetings/Upcoming-Webinars.aspx?hkey=5870d046-0333-465f-aedc-303ab712267c

07/30/2026

Isotopes are integral to the development of nuclear medicine…as long as you don’t swallow the entire world’s supply of plutonium like one pioneer did. In this month’s Uptake, Joe takes us on a journey of the history of isotopes and the key research who developed (and injected) them. Full video on YouTube!

07/24/2026

SNMMI is pleased to announce our annual list of early career professionals selected as “Ones to Watch” in 2026. We are proud to showcase rising talent in the field, offering a platform to increase recognition for early career professionals within our specialty. Congratulations to our 2026 honorees! https://snmmi.org/Web/News/Articles/SNMMI-Announces-Ones-to-Watch-2026-Selections.aspx

07/23/2026

Being able to predict patient outcomes early in a disease course helps providers make important treatment decisions. This is crucial in diseases such as lung cancer, which is the leading cause of cancer-related deaths and is clinically difficult to manage. But a new study in JNM points to an important mortality indicator for metastatic lung cancer: brain metabolism. Learn more

07/21/2026

Total body PET almost didn’t happen. From doubts about its clinical and research applications to reservations about cost, the modality faced many roadblocks. But thanks to the dedication of the team that developed it, total body PET has become a success story: not only is it incredibly effective but patients love its efficiency and effectiveness. Learn more about total body PET in this episode of the JNM Podcast.